Alector, Inc. Profile Avatar - Palmy Investing

Alector, Inc.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment…

Biotechnology
US, South San Francisco [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Alector, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ALEC's Analysis
CIK: 1653087 CUSIP: 014442107 ISIN: US0144421072 LEI: - UEI: -
Secondary Listings
ALEC has no secondary listings inside our databases.